NCT03819660View on ClinicalTrials.gov

Long Term Safety of Amifampridine Phosphate in Spinal Muscular Atrophy 3

PHASE2TerminatedINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

March 7, 2019

Primary Completion Date

September 13, 2021

Study Completion Date

September 13, 2021

Conditions
Spinal Muscular Atrophy Type 3
Interventions
DRUG

Amifampridine Phosphate 10 MG Oral Tablet

Oral tablets

Trial Locations (1)

20133

Neurological Institute Carlo Besta, Milan

Sponsors
All Listed Sponsors
lead

Catalyst Pharmaceuticals, Inc.

INDUSTRY

NCT03819660 - Long Term Safety of Amifampridine Phosphate in Spinal Muscular Atrophy 3 | Biotech Hunter | Biotech Hunter